Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Mifepristone (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2018 Status changed from not yet recruiting to recruiting.
- 09 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.